| HOME >> BIOLOGY >> TECHNOLOGY |
204 824 753
Stock option 3,671 2,600 12,373 9,240
Other 2,002 1,026 6,809 4,110
R&D expense from issuance of
common stock for license - - 11,013 -
Total research and
development expense $17,710 $18,337 $83,352 $57,570
Selling, general and administrative expenses consist primarily of
salaries, travel, office expenses, insurance, professional fees, provision
for doubtful accounts receivable, depreciation and amortization. The table
below summarizes selling, general and administrative expenses by major
categories for the three months and year ended December 31, 2007 and 2006
(dollars in thousands):
Three Months Ended Years Ending
December 31, December 31,
2007 2006 2007 2006
Category:
General and administrative $11,361 $7,300 $34,933 $25,434
Sales and marketing 7,826 4,584 24,159 14,438
Impairment charges 2,068 - 3,582 2,024
Stock option 22,971 7,303 36,353 14,156
Total selling, general
and administrative expense $44,226 $19,187 $99,027 $56,052
For the year ended December 31, 2007, as compared to the year ended
December 31, 2006, the increase in general and administrative expenses was
primarily related to increased expenses for salaries, associated expenses
and other operating expenses from growth in our operations. The increase in
sales and marketing related expenses was primarily related to increased
salaries and an increase in headcount, marketing, travel and associated
expenses from growth in our ope
'/>"/>
| SOURCE United Therapeutics Corporation Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. United States Patent Office Grants CryoCors Request for Patent Interference
2. United Therapeutics to Announce Fourth Quarter and Annual 2007 Financial Results Before Market Open on Tuesday, February 19, 2008
3. Energy Conversion Devices and United Solar Ovonic Enter Into New $55 Million Secured Credit Facility Agreements
4. Nycomeds Ciclesonide to be Commercialised in the United States by Sepracor
5. Chindexs United Family Hospitals and Clinics and NBC Enter into Healthcare Services Agreement
6. Neptune Technologies receives GRAS notification in the United States
7. Essilor: New Acquisitions in the United States and Brazil
8. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
9. Medical Services Begins Working With United States Companies for Distribution of Its Products
10. United Therapeutics Reports Third Quarter 2007 Financial Results
11. Bioponic Phytoceuticals to Roll Out Multiple Products to 1,000 Major Health Food Stores in the Western United States
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |